Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 14/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30095607 | 1.00 | MAT2A (0.50) | MAT2APRMT5CYP1A2CYP3A4FNTA | |
| SCHEMBL24809025 | 0.84 | MAT2A (0.54) | MAT2APRMT5CYP1A2CYP3A4FNTA | |
| SCHEMBL30095865 | 0.84 | MAT2A (0.54) | MAT2APRMT5CYP1A2CYP3A4FNTA | |
| SCHEMBL23577374 | 0.83 | MAT2A (0.33) | MAT2ACSNK2A2CSNK2B | |
| SCHEMBL30961076 | 0.83 | MAT2A (0.33) | MAT2ACSNK2A2CSNK2B | |
| SCHEMBL31169400 | 0.83 | FNTA (0.34) | MAT2AFNTAFNTBCSNK2A2CSNK2B | |
| SCHEMBL23601440 | 0.83 | FNTA (0.34) | MAT2AFNTAFNTBCSNK2A2CSNK2B | |
| SCHEMBL23601377 | 0.82 | CYP11B1 (0.34) | MAT2ACSNK2A2CSNK2BTNF | |
| SCHEMBL24806374 | 0.82 | MAT2A (0.34) | MAT2APRMT5 | |
| Acetic Acid SCHEMBL30146606 | 0.80 | FNTA (0.33) | MAT2AFNTAFNTBCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2022271677-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAT2A 1466/4885PRMT5 1376/4885CYP1A2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.